A Multicenter Phase 2 Open Label Single Arm, Prospective, Interventional Study of Plasma-Derived Factor VIII/VWF in Immune Tolerance Induction Therapy in Subjects with Congenital Hemophilia A

Grants and Contracts Details

StatusFinished
Effective start/end date4/5/1711/10/20

Funding

  • Grifols Worldwide Operations Limited: $14,510.00